Improved AMD treatments and preventive measures required

Article

A study published in Ophthalmology has called for an improvement in preventive measures and novel treatments for early and late age-related macular degeneration (AMD).

A study published in Ophthalmology has called for an improvement in preventive measures and novel treatments for early and late age-related macular degeneration (AMD).

Dr Fridbert Jonasson et al., University of Iceland, Reykjavik, Iceland, conducted a population-based cohort study on 5272 people over 66 years of age. A 45-degree digital camera was used to record fundus images through dilated pupils. The modified Wisconsin Age-Related Maculopathy Grading System was used to assess drusen size, type, area, increased retinal pigment, retinal pigment epithelial depigmentation, neovascular lesions and geographic atrophy (GA).

The findings showed that the prevalence of early AMD was 12.4% for patients aged 66 to 74 years and 36% for those aged 85 years or more. Occurrence of exudative AMD was 3.3% and pure GA was 2.4%. It was found that those aged 85 and above had a higher prevalence of late AMD, with 7.6 % experiencing exudative AMD and 7.6% for pure GA.

From the results it was determined that patients at 85 years old or older are 10 times more likely to develop late AMD than those aged 70-74 years. In an ageing population in Western society improvements in preventive measures and new treatments are, therefore, needed.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.